CTRI/2022/10/046178Not yet recruitingPhase 4
A Multi-centric, Non-Randomized, Open label, Non-Comparative, Active post marketing surveillance to evaluate the Safety and Efficacy of Wikoryl DS oral suspension in children suffering from common cold associated with fever
Trial Snapshot
- Phase
- Phase 4
- Status
- Not yet recruiting
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Pms
Eligibility Criteria
Inclusion Criteria
- •1. Age: 2-12 years of age. (12-40 Kg body weight)
- •2. Genders Eligible for Study: both Males and Females
- •3. Patients with clinical diagnosis of common cold associated with fever. These symptoms may include rhinorrhea, nasal congestion, sneezing etc.
- •4. Patients whose guardians can adhere to the protocol
Exclusion Criteria
- •1. Patients known to be hypersensitive to investigational product
- •2. Patients with severe hepatic or renal dysfunction
Investigators
Similar Trials
Not yet recruiting
Phase 4
Post marketingstudy to evaluate the Safety and Efficacy of Wikoryl Oral Suspension in childreCTRI/2021/12/039023Alembic Pharmaceuticals Limited
Not yet recruiting
Phase 4
Post marketing study to assess the Safety and Efficacy of Wikoryl 10 tablets in adults suffering from common coldCTRI/2022/03/041002Alembic Pharmaceuticals Limited
Completed
Phase 4
Active post marketing surveillance to evaluate the Safety and Efficacy of Sinarest Plus Suspension in children of common cold or allergic rhinitis.CTRI/2021/11/037910Centaur Pharmaceuticals Pvt Ltd420
Completed
Phase 4
Active post marketing surveillance to evaluate the Safety and Efficacy of Sinarest New Tablet in adults of common cold or allergic rhinitis.CTRI/2021/11/037857Centaur Pharmaceuticals Pvt Ltd420
Not yet recruiting
Phase 4
Post marketing study to evaluate the Safety and Efficacy of Wikoryl tablets in adult patientsCTRI/2022/04/042134Alembic Pharmaceuticals Ltd